-
1
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
-
(2005)
N Engl J Med
, vol.353
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues Pereira, J.2
Ciuleanu, T.3
-
2
-
-
22044453790
-
Erlotinib in lung cancer-molecular and clinical predictors of outcome
-
Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
-
(2005)
N Engl J Med
, vol.353
, pp. 133-144
-
-
Tsao, M.S.1
Sakurada, A.2
Cutz, J.C.3
-
3
-
-
43249117388
-
EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
-
Fong T., Morgensztern D., and Govindan R. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. J Thorac Oncol 3 (2008) 303-310
-
(2008)
J Thorac Oncol
, vol.3
, pp. 303-310
-
-
Fong, T.1
Morgensztern, D.2
Govindan, R.3
-
4
-
-
33645805630
-
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas
-
Pham D., Kris M.G., Riely G., Sarkaria I., McDonough T., Chuai S., et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 24 (2006) 1700-1704
-
(2006)
J Clin Oncol
, vol.24
, pp. 1700-1704
-
-
Pham, D.1
Kris, M.G.2
Riely, G.3
Sarkaria, I.4
McDonough, T.5
Chuai, S.6
-
5
-
-
34250161814
-
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial
-
Cappuzzo F., Ligorio C., Janne P.A., et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 25 (2007) 2248-2255
-
(2007)
J Clin Oncol
, vol.25
, pp. 2248-2255
-
-
Cappuzzo, F.1
Ligorio, C.2
Janne, P.A.3
-
6
-
-
33750205340
-
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
-
Asahina H., Yamasaki K., Kinoshita I., Sukoh N., Harada M., Yokouchi H., et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95 (2006) 998-1004
-
(2006)
Br J Cancer
, vol.95
, pp. 998-1004
-
-
Asahina, H.1
Yamasaki, K.2
Kinoshita, I.3
Sukoh, N.4
Harada, M.5
Yokouchi, H.6
-
7
-
-
59249089888
-
-
Paz-Ares L, Sanchez JM, García-Velasco A, Massuti B, López-Vivanco G, Provencio M, et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 2006. ASCO Annual Meeting Proceedings 18S:7020.
-
Paz-Ares L, Sanchez JM, García-Velasco A, Massuti B, López-Vivanco G, Provencio M, et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 2006. ASCO Annual Meeting Proceedings 18S:7020.
-
-
-
-
8
-
-
33746789922
-
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
-
Inoue A., Suzuki T., Fukuhara T., Maemondo M., Kimura Y., Morikawa N., et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 20 24 (2006) 3340-3346
-
(2006)
J Clin Oncol
, vol.20
, Issue.24
, pp. 3340-3346
-
-
Inoue, A.1
Suzuki, T.2
Fukuhara, T.3
Maemondo, M.4
Kimura, Y.5
Morikawa, N.6
-
9
-
-
33846483745
-
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
-
Van Zandwick N., Mathy A., Boerrigter L., Ruijter H., Tielen I., de Jong D., et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann Oncol 18 (2007) 99-103
-
(2007)
Ann Oncol
, vol.18
, pp. 99-103
-
-
Van Zandwick, N.1
Mathy, A.2
Boerrigter, L.3
Ruijter, H.4
Tielen, I.5
de Jong, D.6
-
10
-
-
40049100818
-
Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma
-
Marks J., Broderick S., Zhou Q., Chitale D., Li A., Zakowski M., et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 3 (2008) 111-116
-
(2008)
J Thorac Oncol
, vol.3
, pp. 111-116
-
-
Marks, J.1
Broderick, S.2
Zhou, Q.3
Chitale, D.4
Li, A.5
Zakowski, M.6
-
11
-
-
38949169542
-
Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma
-
Toyooka S., Takano T., Kosaka T., Hotta K., Matsuo K., Ichihara S., et al. Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. Cancer sci 99 (2008) 303-308
-
(2008)
Cancer sci
, vol.99
, pp. 303-308
-
-
Toyooka, S.1
Takano, T.2
Kosaka, T.3
Hotta, K.4
Matsuo, K.5
Ichihara, S.6
|